Du H, Matsushima T, Spyvee M, Goto M, Shirota H, Gusovsky F, Chiba K, Kotake M, Yoneda N, Eguchi Y, DiPietro L, Harmange JC, Gilbert S, Li XY, Davis H, Jiang Y, Zhang Z, Pelletier R, Wong N, Sakurai H, Yang H, Ito-Igarashi H, Kimura A, Kuboi Y, Mizui Y, Tanaka I, Ikemori-Kawada M, Kawakami Y, Inoue A, Kawai T, Kishi Y, Wang Y. Discovery of a potent, metabolically stabilized resorcylic lactone as an anti-inflammatory lead.
Bioorg Med Chem Lett 2009;
19:6196-9. [PMID:
19783437 DOI:
10.1016/j.bmcl.2009.08.096]
[Citation(s) in RCA: 20] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2009] [Revised: 08/26/2009] [Accepted: 08/31/2009] [Indexed: 10/20/2022]
Abstract
With bioactivity-guided phenotype screenings, a potent anti-inflammatory compound f152A1 has been isolated, characterized and identified as the known natural product LL-Z1640-2. Metabolic instability precluded its use for the study on animal disease models. Via total synthesis, a potent, metabolically stabilized analog ER-803064 has been created; addition of the (S)-Me group at C4 onto f152A1 has resulted in a dramatic improvement on its metabolic stability, while preserving the anti-inflammatory activities.
Collapse